FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3095487795> ?p ?o ?g. }

• W3095487795 endingPage "17" @default.
• W3095487795 startingPage "17" @default.
• W3095487795 abstract "INTRODUCTION: Autoantibody effects of monoclonal proteins have been described in multiple organ systems. We previously found a 5-fold higher prevalence than expected of monoclonal gammopathy (MG) in adults with TMA (21% versus 4.2%; Ravindran A et al, Kidney Int 2017). Here we investigated the prevalence of MG in patients undergoing evaluation for TMA with an ADAMTS13 (a disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13) activity assay performed as part of routine clinical care to evaluate for a signal of possible autoantibody pathophysiology in patients with immune thrombotic thrombocytopenic purpura (iTTP). METHODS: WAfter IRB approval, waste plasma samples from patients who had ADAMTS13 activity and inhibitor assay (Lifecodes, ATS-13, Immucor) were archived. Eligible patients included those with the following: i) ADAMTS13 activity level &lt; 30% (n=26), ii) ADAMTS13 activity level &gt;30% but with prior documentation of a value &lt; 30% (n=4). A control cohort (n=49) of patients with ADAMTS13 activity level &gt;30% (and no prior samples with a level &lt; 30% recorded) was also included. Matrix-assisted laser desorption/ionization-time of flight mass spectrometry detection (MALDI-TOF) was used for MG assessment. Mass spectrometry findings of only an IgG kappa MG appearing consistent with rituximab were reviewed and considered negative for MG if the patients had received rituximab prior to sample collection. Medical records were retrospectively reviewed and the following patients were excluded: i) &lt;18 years of age (n=4), ii) iTTP in remission (n=4) at the time of sample collection, and iii) absence of microangiopathy (n=11). RESULTS: Sixty patients met eligibility criteria with the following final diagnoses: iTTP (n=14), transplant-associated TMA (n=12), infection (n=11), malignancy (n=6), complement-mediated TMA (n=5), drug-induced TMA (DITMA; n=5), shock liver (n=2), pancreatitis (n=1), cryoglobulinemia (n=1), and multifactorial (n=3). The median age was 56.5 years (yr) (standard deviation 14.4, range18-81) and 58% of patients were female. The median age was similar among patients with (57 yr) and those without MG (56 yr). Median ADAMTS-13 activity of the whole study population was 52% (0-100%); 6/14 patients with an inhibitor screen performed on the same sample had a positive result; median titer was 1.2 Bethesda units (range &lt;0.4 - 2.8). Treatments of the acute presentation included corticosteroids (n=32), plasma exchange (n=21), rituximab (n=9), and eculizumab (n=4). None of these patients received a multiple myeloma-type treatment regimen as part of their acute management. A MG was identified in 25 patients: monoclonal in 14 patients, biclonal in 10 patients, and triclonal in 1 pt. Among the 14 patients with a single monoclonal protein, the distribution of heavy and light chains was as follows: IgG (9; 64%), IgM (3; 21%), IgA (2; 14%), lambda (8; 57%), kappa (6; 43%). Receipt of immune-modifying treatment at the time of sample draw was identified in 24 patients (9/25 with a monoclonal protein, 15/35 without a monoclonal protein; not statistically significant by 2-tail Fisher's exact test [p=0.79]), including cancer-directed therapy (n=9), graft-versus-host disease prophylaxis (n=8), solid organ transplant anti-rejection therapy (n=5), and autoimmune disease treatment (n=2). Overall, the proportion of patients with monoclonal gammopathy was similar between iTTP and other diagnoses, detailed in Table 1. Among the 14 pt with iTTP, 4 had a monoclonal protein (IgG kappa [n=2], IgA lambda [n=2]). Additionally, 1 pt with iTTP had biclonal proteins (IgG kappa and IgA kappa), which was consistent with a known prior history of monoclonal gammopathy of undetermined significance. A monoclonal protein was present in 2 of the 6 pt with a detectable inhibitor titer (0.6 and &lt;0.4 Bethesda units). CONCLUSIONS: Patients undergoing evaluation for iTTP with ADAMTS-13 activity testing had a high prevalence of monoclonal proteins across variable underlying diagnoses. In this heterogeneous cohort there was no significant association between iTTP and the presence of MG to support an autoantibody pathophysiologic role. Disclosures Murray: The Binding Site: Patents & Royalties: Patent Use of Mass Spec to identify monoclonal proteins licensed to The Binding Site. Pruthi:HEMA Biologics: Honoraria; Instrumentation Laboratory: Honoraria; Merck: Honoraria; CSL Behring: Honoraria; Genentech Inc.: Honoraria; Bayer Healthcare: Honoraria." @default.
• W3095487795 created "2020-11-09" @default.
• W3095487795 creator A5001330715 @default.
• W3095487795 creator A5016151411 @default.
• W3095487795 creator A5029802364 @default.
• W3095487795 creator A5041356401 @default.
• W3095487795 creator A5051563559 @default.
• W3095487795 creator A5090092577 @default.
• W3095487795 date "2020-11-05" @default.
• W3095487795 modified "2023-10-01" @default.
• W3095487795 title "Detection of Monoclonal Immunoglobulin By Mass Spectrometry in Patients Evaluated for Thrombotic Microangiopathy (TMA)" @default.
• W3095487795 doi "https://doi.org/10.1182/blood-2020-137546" @default.
• W3095487795 hasPublicationYear "2020" @default.
• W3095487795 type Work @default.
• W3095487795 sameAs 3095487795 @default.
• W3095487795 citedByCount "0" @default.
• W3095487795 crossrefType "journal-article" @default.
• W3095487795 hasAuthorship W3095487795A5001330715 @default.
• W3095487795 hasAuthorship W3095487795A5016151411 @default.
• W3095487795 hasAuthorship W3095487795A5029802364 @default.
• W3095487795 hasAuthorship W3095487795A5041356401 @default.
• W3095487795 hasAuthorship W3095487795A5051563559 @default.
• W3095487795 hasAuthorship W3095487795A5090092577 @default.
• W3095487795 hasBestOaLocation W30954877951 @default.
• W3095487795 hasConcept C126322002 @default.
• W3095487795 hasConcept C159641895 @default.
• W3095487795 hasConcept C2777878052 @default.
• W3095487795 hasConcept C2778585876 @default.
• W3095487795 hasConcept C2779134260 @default.
• W3095487795 hasConcept C2779338263 @default.
• W3095487795 hasConcept C2780653079 @default.
• W3095487795 hasConcept C2780921031 @default.
• W3095487795 hasConcept C2781203188 @default.
• W3095487795 hasConcept C71924100 @default.
• W3095487795 hasConcept C89560881 @default.
• W3095487795 hasConcept C90924648 @default.
• W3095487795 hasConceptScore W3095487795C126322002 @default.
• W3095487795 hasConceptScore W3095487795C159641895 @default.
• W3095487795 hasConceptScore W3095487795C2777878052 @default.
• W3095487795 hasConceptScore W3095487795C2778585876 @default.
• W3095487795 hasConceptScore W3095487795C2779134260 @default.
• W3095487795 hasConceptScore W3095487795C2779338263 @default.
• W3095487795 hasConceptScore W3095487795C2780653079 @default.
• W3095487795 hasConceptScore W3095487795C2780921031 @default.
• W3095487795 hasConceptScore W3095487795C2781203188 @default.
• W3095487795 hasConceptScore W3095487795C71924100 @default.
• W3095487795 hasConceptScore W3095487795C89560881 @default.
• W3095487795 hasConceptScore W3095487795C90924648 @default.
• W3095487795 hasIssue "Supplement 1" @default.
• W3095487795 hasLocation W30954877951 @default.
• W3095487795 hasOpenAccess W3095487795 @default.
• W3095487795 hasPrimaryLocation W30954877951 @default.
• W3095487795 hasRelatedWork W2022810605 @default.
• W3095487795 hasRelatedWork W2124400226 @default.
• W3095487795 hasRelatedWork W2946198964 @default.
• W3095487795 hasRelatedWork W3033753898 @default.
• W3095487795 hasRelatedWork W3037949192 @default.
• W3095487795 hasRelatedWork W3095487795 @default.
• W3095487795 hasRelatedWork W3104949179 @default.
• W3095487795 hasRelatedWork W3159566231 @default.
• W3095487795 hasRelatedWork W4285801222 @default.
• W3095487795 hasRelatedWork W2036500077 @default.
• W3095487795 hasVolume "136" @default.
• W3095487795 isParatext "false" @default.
• W3095487795 isRetracted "false" @default.
• W3095487795 magId "3095487795" @default.
• W3095487795 workType "article" @default.